MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones

MeiraGTx Holdings plc

Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.
Lilly gets exclusive worldwide rights to AAV-AIPL1 for LCA4, which restored vision in 11 blind children.
Also licenses proprietary intravitreal capsids, promoters (AI-generated), and riboswitch gene-editing rights.
MeiraGTx eligible for tiered royalties; retains ownership of certain technology improvements; Lilly funds all R&D and commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.